Journal Article

Efficacy and drug interactions of the new HMG‐CoA reductase inhibitors cerivastatin and atorvastatin in CsA‐treated renal transplant recipients

Lutz Renders, Irmgard Mayer‐Kadner, Christine Koch, Sabine Schärffe, Klaus Burkhardt, Roland Veelken, Roland. E. Schmieder and Ingeborg A. Hauser

in Nephrology Dialysis Transplantation

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 16, issue 1, pages 141-146
Published in print January 2001 | ISSN: 0931-0509
Published online January 2001 | e-ISSN: 1460-2385 | DOI: http://dx.doi.org/10.1093/ndt/16.1.141
Efficacy and drug interactions of the new HMG‐CoA reductase inhibitors cerivastatin and atorvastatin in CsA‐treated renal transplant recipients

Show Summary Details

Preview

Background. Hyperlipidaemia is an important risk factor for cardiovascular disease in renal transplant recipients. The aim of this study was to test the efficacy and possible drug–drug interactions of the new HMG‐CoA reductase inhibitors (statins) atorvastatin and cerivastatin in cyclosporin A (CsA)‐treated renal transplant patients.

Subjects and methods. Thirty patients with stable graft function and LDL cholesterol of 130 mg/dl were randomly assigned to active treatment groups (10 mg atorvastatin or 0.2 mg cerivastatin), or a control group. CsA blood trough levels were controlled on a weekly basis and adapted if they changed more than 25% from baseline values (100–150 ng/ml). Lipid levels and routine laboratory parameters before and after a treatment period of 3 months were compared.

Results. In the group treated with cerivastatin no significant changes in CsA blood trough levels occurred (CsA 116±21 ng/ml vs 110±20 ng/ml). In contrast, in the group treated with atorvastatin, four of 10 patients had a rise in CsA blood trough levels of more than 25% within 7–14 days of starting therapy. In the remaining patients no significant changes in CsA drug levels occurred. After therapy with atorvastatin or cerivastatin, total cholesterol, LDL cholesterol, and triglycerides were significantly lower compared with baseline conditions. No changes of CsA or lipoprotein levels were present in the control group.

Conclusion. In our study population both statins were very effective in lowering elevated LDL cholesterol levels. Cerivastatin did not influence CsA blood trough levels, whereas atorvastatin increased CsA levels in four of 10 patients. Further research in a larger study is necessary in order to confirm these results and to investigate the possible reasons for this drug interaction.

Keywords: atorvastatin; cerivastatin; cyclosporin A; cytochrome P450; hyperlipidaemia; renal transplantation

Journal Article.  3479 words.  Illustrated.

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.